Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 313

1.

Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era.

Ercole B, Marietti SR, Fine J, Albertsen PC.

J Urol. 2008 Oct;180(4):1336-9; discussion 1340-1. doi: 10.1016/j.juro.2008.06.027. Epub 2008 Aug 15.

PMID:
18707696
2.

What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.

Barocas DA, Cowan JE, Smith JA Jr, Carroll PR; CaPSURE Investigators.

J Urol. 2008 Oct;180(4):1330-4; discussion 1334-5. doi: 10.1016/j.juro.2008.06.019. Epub 2008 Aug 15.

PMID:
18707731
4.

Insignificant prostate cancer and active surveillance: from definition to clinical implications.

Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, Stief CG, Schröder F.

Eur Urol. 2009 Jun;55(6):1321-30. doi: 10.1016/j.eururo.2009.02.028. Epub 2009 Mar 6. Review.

PMID:
19286302
5.

Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.

Harlan SR, Cooperberg MR, Elkin E, Lubeck DP, Meng M, Mehta SS, Carroll PR.

J Urol. 2003 Nov;170(5):1804-7.

6.

Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.

Loeb S, Nadler RB, Roehl KA, Antenor JA, Catalona WJ.

J Urol. 2007 May;177(5):1745-8.

PMID:
17437803
7.

13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort.

Albertsen PC, Hanley JA, Penson DF, Barrows G, Fine J.

J Urol. 2007 Mar;177(3):932-6.

PMID:
17296379
8.

Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.

Tan N, Lane BR, Li J, Moussa AS, Soriano M, Jones JS.

J Urol. 2008 Oct;180(4):1325-9; discussion 1329. doi: 10.1016/j.juro.2008.06.022. Epub 2008 Aug 15.

PMID:
18707706
9.

Uncertainty and quality of life among men undergoing active surveillance for prostate cancer in the United States and Ireland.

Hegarty JM, Wallace M, Comber H.

Am J Mens Health. 2008 Jun;2(2):133-42. doi: 10.1177/1557988307300467. Epub 2007 May 23.

PMID:
19477777
10.

Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.

San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC.

J Urol. 2011 Feb;185(2):471-6. doi: 10.1016/j.juro.2010.09.115. Epub 2010 Dec 17.

PMID:
21167525
11.

Staging saturation biopsy in patients with prostate cancer on active surveillance protocol.

Abouassaly R, Lane BR, Jones JS.

Urology. 2008 Apr;71(4):573-7. doi: 10.1016/j.urology.2007.11.094.

PMID:
18387385
12.

Active surveillance for prostate cancer: has the time finally come?

Aragon-Ching JB.

J Clin Oncol. 2010 Jun 1;28(16):e265-6; author reply e267. doi: 10.1200/JCO.2010.28.1584. Epub 2010 Apr 20. No abstract available.

PMID:
20406916
13.

Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.

Capitanio U, Karakiewicz PI, Valiquette L, Perrotte P, Jeldres C, Briganti A, Gallina A, Suardi N, Cestari A, Guazzoni G, Salonia A, Montorsi F.

Urology. 2009 May;73(5):1087-91. doi: 10.1016/j.urology.2008.10.048. Epub 2009 Feb 4.

PMID:
19195695
14.

Active surveillance for favorable-risk prostate cancer: what are the results and how safe is it?

Klotz L.

Curr Urol Rep. 2007 Sep;8(5):341-4. Review. No abstract available.

PMID:
17880830
15.

The face of high risk prostate cancer.

Albertsen PC.

World J Urol. 2008 Jun;26(3):205-10. doi: 10.1007/s00345-008-0254-3. Epub 2008 Apr 10.

PMID:
18401585
16.

Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.

Albertson PC.

Eur Urol. 2009 Jun;55(6):1331-2. doi: 10.1016/j.eururo.2009.02.029. Epub 2009 Mar 6. No abstract available.

PMID:
19286304
17.

Racial variations in the performance of prostate specific antigen and prostate specific antigen density in the era of extended prostate biopsy schemes.

Elliott CS, Shinghal R, Presti JC Jr.

J Urol. 2008 Oct;180(4):1318-23; discussion 1323-4. doi: 10.1016/j.juro.2008.06.031. Epub 2008 Aug 15.

PMID:
18707710
18.
19.

Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer.

Reed A, Ankerst DP, Pollock BH, Thompson IM, Parekh DJ.

J Urol. 2007 Nov;178(5):1929-32; discussion 1932. Epub 2007 Sep 17.

PMID:
17868724
20.

Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml.

Loeb S, Roehl KA, Nadler RB, Yu X, Catalona WJ.

J Urol. 2007 Dec;178(6):2348-52; discussion 2352-3. Epub 2007 Oct 22.

PMID:
17936844

Supplemental Content

Support Center